EBV+ PTLD Pathogenesis
EBV+ PTLD Pathogenesis
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) is a rare, acute and potentially life-threatening group of lymphoid disorders that arise after transplantation4,5.
DNA, deoxyribonucleic acid; EBV+, Epstein-Barr virus positive; PTLD, post-transplant lymphoproliferative disease
PROGNOSIS
The poor patient prognosis associated with EBV+ PTLD upon rituximab-based treatment failure calls for an urgent intervention6,7.
In post HCT, the median OS post rituximab +/- chemotherapy failure is 0.7 months6
In post SOT, the median OS post rituximab +/- chemotherapy failure is 4.1 months7